In a transformative move for Taiwan's pharmaceutical landscape, Easywell Biomedicals and Genovate Biotechnology announced a definitive merger agreement via a share swap on March 12. Based on independent expert evaluations, the exchange ratio is set at 0.909 shares of Awi for 1 share of Genovate Biotechnology. Upon completion, Genovate Biotechnology will delist and integrate into the Awi ecosystem. Shareholder meetings for both firms are scheduled for April 22.

• Strategic Synergy: Awi Chairman Han-Fei Lin emphasized that the merger creates a rare "Taiwan-US Dual-Base" platform. Awi brings a high-efficiency track record in US FDA regulatory affairs—having secured an approval in as little as 11 months—and operates a US-based GMP facility with 9 drug licenses (including 3 NDAs).
• Complementary Strengths: Genovate Biotechnology contributes deep R&D foundations in Taiwan, a robust injectable production line, and a comprehensive domestic sales force. Genovate Biotechnology Chairman C.Y. Chen noted that the alliance directly aligns with President Lai’s "Drug Resilience" policy by securing localized manufacturing while leveraging Awi’s expertise in controlled-release formulations for CNS and pediatric medicine.

Resource: 震撼彈！易威以0.909比1換股併購健亞 打造台美雙基地藥廠